Policy | September 21, 2021
AYUSH minister Sonowal exhorts researchers to explore Indian traditional medicine
Assam is home to more than 1,700 species of medicinal plants
Assam is home to more than 1,700 species of medicinal plants
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
Textiles treated with the technology have also been proven to deactivate viruses, including SARS-CoV-2 (the virus that causes COVID-19).
Domestic business was up 41.9% YoY and 27.7% QoQ
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Domestic market and developing countries will need doses of Indian vaccines
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
Subscribe To Our Newsletter & Stay Updated
